AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 71602
Drug: (−)‐deprenyl with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)‐deprenyl with smaller total daily doses of levodopa and a peripheral decarboxylase inhibitor
Trial: 30942013
Drug: Intradermal needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal needling after pterygium resection
Trial: 23137103
Drug: Propofol (1%)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (1%) administered at a dose of 3 mg·kg(‐1) intravenously, maintained by propofol infusion (0.5%) at 12 mg·kg(‐1·) h(‐1) for the first 20 min and at 8 mg·kg(‐1·) h(‐1) thereafter
Trial: 16373890
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hypoglycemia with 15 g of oral glucose
Trial: 12727976
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 0.043 mg/kg x d
Trial: 25742759
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg losartan
Trial: 25742759
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in SCr >0.3 mg/dl
Trial: 25742759
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in SCr >0.3 mg/dl before 4 months
Trial: 20622687
Drug: Clevidipine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevidipine (0.5 mg/mL in 20% lipid solution, initiated at 10 mg/h and titrated to effect)
Trial: 8252157
Drug: Ceftazidime alone
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime alone 3 g/day (Group C)
Trial: 8252157
Drug: Ceftazidime 3
RxNorm normalized name: ceftazidime 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 3 g/day plus amikacin 15 mg/kg/day (Group CA)
Trial: 8252157
Drug: Ceftazidime 3
RxNorm normalized name: ceftazidime 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 3 g/day plus vancomycin 1.5 g/day (Group CV)
Trial: 15939243
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) therapy for 2 months
Trial: 8916749
Drug: Xylitol chewing
RxNorm normalized name: xylitol Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol chewing gum (8.4 g a day)
Trial: 1927519
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) dose regimen of 15 IU/m2/week as daily s.c. injections
Trial: 1927519
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) dose regimen of 30 IU/m2/week
Trial: 6350994
Drug: Intravenous guanethidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous guanethidine block
Trial: 30732624
Drug: Carer-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carer-administration of as-needed subcutaneous medication for breakthrough symptoms (pain, nausea, restlessness, noisy breathing) with manualised training package delivered by local nursing team.
Trial: 7575714
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg/day)
Trial: 20884622
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor lysate- and KLH-pulsed DC vaccine
Trial: 25098116
Drug: Conventional prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional prevention (topical corticosteroids)
Trial: 22989898
Drug: Intensive SBP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive SBP reduction (to <=140mmHg) using intravenous nicardipine infusion for 24 hours post-randomization
Trial: 18021872
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks
Trial: 16040446
Drug: High-dose xylitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose xylitol (HX; 6.0 g xylitol)
Trial: 16040446
Drug: Low-dose xylitol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose xylitol (LX; 2.0 g xylitol)
Trial: 8009976
Drug: Interferon-beta (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta (2 x 10(6) I.U. daily) for ten days
Trial: 8009976
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml of saline solution daily) for ten days
Trial: 2782336
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: Clindamycin and tobramycin for >= 48 hours followed by 7-day course of oral Augmentin
Trial: 29300197
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution (25%; 0.5 mL/kg) administered 2 minutes before procedures
Trial: 22622278
Drug: EMDR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR treatment with one-week sessions
Trial: 22622278
Drug: Sertraline (SSRI)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (SSRI) treatment
Trial: 20195553
Drug: Patient-controlled oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled oral analgesia (PCOA)
Trial: 20195553
Drug: RN-administered short-acting
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RN-administered short-acting oral opioids
Trial: 20195553
Drug: RN administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RN administration
Trial: 15956047
Drug: Iron medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron medicine (ferrous gluconate at 3 mg/kg of elemental iron once daily)
Trial: 15956047
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified follow-on milk (12 mg/l ferrous iron)
Trial: 15956047
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified partially modified cows' milk (12.9 mg/l ferrous iron)
Trial: 12095498
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of clomiphene citrate (CC) on days 1-5
Trial: 1922235
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg (oral)
Trial: 1922235
Drug: Cefixime 800
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime 800 mg (oral)
Trial: 1922235
Drug: Ceftriaxone 250
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 250 mg (intramuscular)
Trial: 6981167
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) - 160 mg of TMP plus 800 mg of SMZ, two double-strength tablets twice daily for two days
Trial: 6981167
Drug: Ampicillin plus
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin plus probenecid - 3.5 g of ampicillin plus 1 g of probenecid, single dose
Trial: 30819688
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TA) 4 mg
Trial: 29402270
Drug: Sitagliptin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin treatment group
Trial: 27621258
Drug: Self-help cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help cognitive behaviour therapy (CBT) intervention lasting 4 weeks
Trial: 27621258
Drug: No treatment-wait
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment-wait control condition (NTWC)
Trial: 20197013
Drug: Saquinavir/ritonavir 1,000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir/ritonavir 1,000/100 mg twice daily for 2 weeks
Trial: 20197013
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline digoxin dose of 0.5 mg)
Trial: 17437688
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs); specific dosage and duration not available
Trial: 15560958
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day clozapine
Trial: 15560958
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day clozapine
Trial: 15560958
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day clozapine
Trial: 15560958
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day clozapine (heavy smokers)
Trial: 12930926
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) given concurrently with chemotherapy
Trial: 12930926
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) in standard-risk AML
Trial: 12930926
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF in standard-risk AML
Trial: 12930926
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) in unfavorable prognosis subgroup
Trial: 10519559
Drug: Flexion‐distraction technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexion‐distraction technique (active treatment)
Trial: 10519559
Drug: Sham adjustments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham adjustments (placebo treatment)
Trial: 2391397
Drug: Acetaminophen sustained
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen sustained release (SR) high dose (2000 mg)
Trial: 2391397
Drug: Acetaminophen immediate
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen immediate plus sustained release (IR + SR) high dose (500 + 1500 mg)
Trial: 2391397
Drug: Acetaminophen standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen standard tablet high dose (1000 mg)
Trial: 2391397
Drug: Acetaminophen standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen standard tablet low dose (500 mg)
Trial: 2391397
Drug: Acetaminophen sustained
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen sustained release (SR) low dose (1000 mg)
Trial: 2391397
Drug: Acetaminophen immediate
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen immediate plus sustained release (IR + SR) low dose (250 + 750 mg)
Trial: 24552803
Drug: Personal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal oxygen supplement (OS)
Trial: 17913322
Drug: Lithium administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium administration for two weeks
Trial: 21960699
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol 2.5 mg
Trial: 16002915
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol 5 mg
Trial: 1710624
Drug: 24 IU
RxNorm normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 IU GH administered intramuscularly on alternate days starting on cycle day 4
Trial: 1710624
Drug: Placebo (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile saline) administered intramuscularly on alternate days starting on cycle day 4
Trial: 1710624
Drug: 24 IU
RxNorm normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 IU GH administered intramuscularly
Trial: 6798616
Drug: Alprazolam (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25, 0.5, and 1.0 mg)
Trial: 6798616
Drug: Diazepam (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2, 5, and 10 mg)
Trial: 31994365
Drug: Oxycodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10 mg)/Naloxone (5 mg) for the first 48 hours
Trial: 31994365
Drug: Morphine (0.2-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.2-0.4 mg/kg/day)
Trial: 25373836
Drug: Patient requests
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient requests for pain medications
Trial: 19320662
Drug: Vildagliptin plus
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily)
Trial: 19320662
Drug: Vildagliptin plus
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin plus low-dose metformin combination therapy (50 mg + 500 mg twice daily)
Trial: 19320662
Drug: Vildagliptin monotherapy
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin monotherapy (50 mg twice daily)
Trial: 19320662
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin monotherapy (1000 mg twice daily)
Trial: 19320662
Drug: Vildagliptin plus
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin plus high-dose metformin combination therapy
Trial: 19320662
Drug: Vildagliptin plus
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin plus low-dose metformin combination therapy
Trial: 8021335
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine (M-5041T), 6 mg applied for 3 days
Trial: 8021335
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (Catapres), 0.075 mg every 12 hours for 3 days
Trial: 8021335
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine (M-5041T)
Trial: 8021335
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (Catapres)
Trial: 2739347
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no preoperative chemotherapy)
Trial: 23999956
Drug: 6-session intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-session intervention including trauma-focused treatments (psychoeducation, cognitive restructuring, progressive muscle relaxation, development of trauma narrative) and infant redefinition
Trial: 20615632
Drug: Ultrahigh PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrahigh PSA levels (≥50 ng/ml)
Trial: 16765182
Drug: No BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BCG treatment (control group)
Trial: 16765182
Drug: BCG therapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG therapy with maintenance treatment
Trial: 16765182
Drug: BCG therapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG therapy for papillary carcinoma
Trial: 16765182
Drug: BCG plus
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG plus chemotherapy/immunotherapy
Trial: 9552503
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during excimer laser angioplasty
Trial: 31479530
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus reuteri lozenges, used twice-daily for 28 days as an adjunct to NSPT
Trial: 31479530
Drug: Placebo lozenges,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges, used twice-daily for 28 days as an adjunct to NSPT
Trial: 31479530
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus reuteri lozenges
Trial: 28222678
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg (Group D1)
Trial: 28222678
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg/kg (Group D2)
Trial: 19547873
Drug: Isoniazid chemoprophylaxis
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid chemoprophylaxis (300 mg/day) for six months
Trial: 16787996
Drug: Bias-adjusted parameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bias-adjusted parameter estimator for the treatment coefficient
Trial: 16787996
Drug: Point estimator
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point estimator for treatment effect
Trial: 11642624
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of oral acyclovir treatment (80 mg/kg/day up to a maximum of 3,200 mg/day in four divided doses) starting within 24 hours of rash onset (Group A)
Trial: 11642624
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of acyclovir treatment starting on the first day of rash (Group B1)
Trial: 11642624
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of acyclovir treatment starting on the second day of rash (Group B2)
Trial: 11642624
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A subjects (acyclovir treatment within 24 hours of rash onset)
Trial: 9374086
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2 at intervals of 30 minutes, 4 hours, and 24 hours every 3 weeks
Trial: 9374086
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2
Trial: 23148731
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg lacosamide oral tablet
Trial: 23148731
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg lacosamide oral syrup
Trial: 23148731
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of tablet and syrup formulations
Trial: 23148731
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of lacosamide
Trial: 22130748
Drug: Supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised treatment in out-patients for schizophrenia (STOPS)
Trial: 19387363
Drug: Normoxia (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoxia (placebo group inhaled normoxic air)
Trial: 3317337
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of captopril and nifedipine
Trial: 29420951
Drug: 5‐fluorouracil (subconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (subconjunctival injection)
Trial: 26660000
Drug: Both techniques
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both techniques (DGG-L and DGG-B)